1. Lobaplatin Inhibits Prostate Cancer Proliferation and Migration Through Regulation of BCL2 and BAX. Issue 2 (4th June 2019) Authors: Cao, Hongwen; Feng, Yigeng; Chen, Lei; Yu, Chao Journal: Dose-response Issue: Volume 17:Issue 2(2019:Apr./Jun.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Repression of MicroRNA‐372 by Arsenic Sulphide Inhibits Prostate Cancer Cell Proliferation and Migration through Regulation of large tumour suppressor kinase 2. Issue 3 (28th December 2016) Authors: Cao, Hongwen; Feng, Yigeng; Chen, Lei Journal: Basic & clinical pharmacology & toxicology Issue: Volume 120:Issue 3(2017) Page Start: 256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. TRIM66 promotes malignant progression of prostate carcinoma through the JAK/STAT pathway. Issue 4 (3rd March 2020) Authors: Cao, Hongwen; Gao, Renjie; Chen, Lei; Feng, Yigeng Journal: FEBS open bio Issue: Volume 10:Issue 4(2020) Page Start: 515 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal. (30th May 2018) Authors: Chen, Lei; Cao, Hongwen; Yu, Chao; Feng, Yigeng Journal: Fundamental & clinical pharmacology Issue: Volume 32:Number 5(2018) Page Start: 548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗